A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer

"Induction therapy regimen：Iparomlimab and Tuvonralimab 5 mg/kg, every 3 weeks (q3w), administered via intravenous infusion. Paclitaxel polymer micelles in combination with platinum: In cycle 1, paclitaxel polymer micelles 230 mg/m² administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min. In cycle 2, if the patient's nadir neutrophil count is ≥1.0×10⁹/L and the nadir platelet count is ≥80×10⁹/L after cycle 1, and no grade II-IV non-hematologic toxicities have occurred, then paclitaxel polymer micelles 300 mg/m² will be administered via intravenous infusion over ≥3 hours, followed by cisplatin 70 mg/m² or carboplatin AUC 5 mg/mL/min.~The local treatment regimen is either surgery or standard radiotherapy. The consolidation therapy regimen consists of Iparomlimab and Tuvonralimab for 1 year , with the decision to combine with chemotherapy left to the discretion of the treating physician on an individual basis."